Background: Advanced paternal and/or maternal age is a classic risk factor for Down syndrome. The aim of the study was to investigate the frequency of Down syndrome types in children and its association with maternal and paternal age in Bosnia and Herzegovina. Subjects and Methods: The cross sectional, observational study included 127 children, 49 girls and 78 boys, aged 1-180 months suspected to have Down syndrome, admitted to the Centre for Genetics, Faculty of Medicine University of Sarajevo, for cytogenetic analysis and differential diagnosis of Down syndrome during the period from January 2010 to May 2015. Standard method of 72 hours cultivation of peripheral blood lymphocytes has been applied. The accepted level of statistical significance was p<0.05. Study Results: The most common type of Down syndrome was standard trisomy (86.6%), comparing to translocation and mosaicism (7.1%; 6.3%, respectively). The highest frequency of Down syndrome cases was in mother and father’s group from 30-39 years old (57; 57 children, respectively) compared to mother and father’s groups with younger than 30 (44; 29, respectively) and 40 and older (26; 41, respectively). The significant difference was found in maternal age between translocation and mosaicism groups (p=0.036). Difference between parental years and type of Down syndrome was significant when Standard trisomy 21 and translocation (p=0.045), as well as mosaicism and translocation (p=0.036), were compared. Conclusion: The most common type of Down syndrome was standard trisomy 21, with highest occurrence in parents from 30 to 39 years old. Parents were the youngest in translocation group. Obtained results suggest that multidisciplinary approach to identifying the trigger for trisomy appearance and the influence of maternal age is required.

Introduction: Glaucoma is the second leading cause of blindness in the world and represents a significant social and health problem. Early detection of glaucoma enables early initiation of treatment and may delay disease progression. The aim of this work is to determine whether it is possible to detect glaucoma in early stages. Methods: A public awareness campaign was carried out in University Clinic Center (UCC) in Tuzla, Bosnia and Herzegovina (B&H) during 2012, 2013, 2014 and 2015 Glaucoma Week, with one-day, free of charge screening of individuals. This screening program was composed of getting brief medical history, slit-lamp examination including intraocular pressure and anterior chamber dept evaluation and non-mydriatic fundus exam with evaluation of the cup/disk ration. Results: A total of 682 individuals were screened, 277 were male and 405 were female. The youngest individual was 8 years old and the oldest individual was 84 years old. The mean age was 57.6 years. Intraocular pressure higher then 21,9 mmHg was found in 83 patients. Conclusion: Glaucoma is a disease that affects visual acuity and gradually leads to blindness. It occurs in all age groups in both sexes and in all races. Early detection of disease and proper treatment can prevent permanent loss of vision. Detection and early treatment of glaucoma must become one of the leading public health programs in B&H.

Objectives: The association of inflammatory reactions with almost all types of cancer supports the concept that inflammation is a critical component of tumor progression. The present study aimed to evaluate the relationship of serum markers of chronic inflammation with the stage of and histopathological size of colorectal carcinoma (CRC). Methods: This cross-sectional study included 90 patients of both sexes, mean age 66.2 (range 47-78) years, with clinically and histologically confirmed CRC, who were admitted to the Clinic for abdominal surgery UCCS for surgical treatment of CRC. The patients according to the stage of disease were divided into three groups (stage II–IV). The control group consisted of 30 subjects with no signs of malignancy and acute inflammatory diseases. Staging of CRC was done according to the TNM classification. In each patient, the preoperative blood samples were taken for determination of the parameters of inflammation: the erythrocyte sedimentation rate, white blood cells, C-reactive protein (CRP), fibrinogen and alpha 2 globulins. Results: It was confirmed that increasing markers of inflammation followed increasing stages of colorectal cancer, depth of tumor invasion and the occurrence of metastatic disease. CRP is a biomarker that consistently and significantly increases from the second to the fourth stage of colorectal cancer (7.2 (2.3-14.6) mg/L vs. 21.85 (12.3-41) mg/L vs. 38.6 (21.5-79) mg/L; p<0.01) and significantly correlates positively with the stage of CRC (r= 0.783, p<0.001), and the tumor size (r=0.249, p<0.05). Conclusion: The study results point to an increase in the degree of chronic inflammation throughout the progression of colorectal cancer. The most consistent marker of chronic inflammation that accompanies the progression of colorectal carcinoma is CRP.

Contemporary forms of business in tourism impose new trends conditioned by an ever-increasing number of tourists travelling in the world today. It is an undeniable fact that tourists are increasingly demanding and that it is not a simple task to satisfy all their needs and expectations. Tourist satisfaction is an important strategic weapon on which success of a tourist destination is dependent. Customer satisfaction often results in prolonged stay in a tourist place, which is certainly dependent on a fair relationship between the service user and provider, but also on the way in which that service has been delivered. Meeting the expected level of satisfaction should be a common attitude, as the emotional reaction of the visitor is based on the difference between the expected and the delivered service. A basic indicator of customer satisfaction in tourism are revisits of a tourist destination. Guests visit many destinations several times during their lifetimes, which clearly indicates that satisfaction with time spent at a certain place leads to the intention of revisiting. On the other hand, an increasingly large share of family business in tourism, especially the accommodation sector, can be directly related to the tendency of achieving tourist satisfaction through an experience based on a direct contact with service providers. Successful hosts have already realized that their guests must not be perceived merely as numbers, but need to strive towards creating a personal relationship that would generate satisfaction. The practice of renting out accommodation in private homes and households has been present in Montenegro for decades. Moreover, that form of accommodation is numerically superior to all other kinds. The goal of this paper is to explore the satisfaction of customers with services offered on tourist destinations and to establish in what way it affects the successfulness of family business based on private accommodation facilities. Research described in this paper was conducted in the coastal town of Sutomore (Bar municipality) in the Republic of Montenegro, which has been recording a significant growth of tourist visits in the recent years. The paper demonstrates the results of survey research created according to the qualitest model, conducted on a sample of 160 tourists accommodated in private accommodation premises. The results obtained will serve to propose measures for improvement the tourism offer.

Systemic lupus erythematosus (SLE) is a disease of unknown etiology in which tissues and cells are damaged by pathogenic autoantibodies and immune complexes. About ninety percent of patients with lupus are women between the ages of 20 and 40. The disease may affect only one organ system, and it also can be a multisystem and affect the skin, joints, kidneys, lungs, nervous system, and serous membrane. In the case report is presented a 38 year old patient with severe systemic lupus erythematosus, which adequately reacted to the treatment of mycophenolate mofetil. Keywords: Systemic lupus erythematosus, the effect of therapy, mycophenolate mofetil. (Scr Med 2016:47:74-75) ( ) * + , . , / 0 1 0 2 3 4 5 4 . 4 3 . 6 . , 7 . , 8 9 : ; + 7 , 7 < = . 0 = > ? @ A B B . C B < A : + 0 1 / / / Introduction D E F G H I J K L M N M F H O E G P H I Q G R F M F S D T U V J F Q W J F H Q F H R X M Y Z [ Y R \ Y H G J R L R ] E J Y \ P J K P G J F F M H F Q Y W K H L L F Q O H W Q I Q ] H W ^ E N Q G P R ] H Y J K Q M G R Q Y G J ^ R W J H F Q Y W J I I M Y H K R I N L H _ H F ` a b J Y H G E N H O K H Y G R X L M N M F N Q G J H Y G F Q O H \ R I H Y c M F M Q L L E J Y G P H O H N O R W M K G J d H F G Q ] H R X L J X H c ^ M G K P J L W O H Y c H L W H O L E Q Y W I H Y K Q Y Q L F R ^ H K R I H J Y X H K G H W ` e D T U J F I Q Y J X H F G H W ^ E F M ^ Z f H K G J d H Q Y W K L J Y J K Q L F J ] Y F M F M Q L L E R Y G P H F [ J Y c f R J Y G F Q Y W J Y G H O Y Q L R O ] Q Y F ` g R R W [ Y R \ L H W ] H R X G P H N Q G J H Y G Q Y W G P H Q K G J d J G J H F R X P J F h P H O F J L L Y H F F Q Y W W J F H Q F H K R M O F H Q O H W H K J Z F J d H X Q K G R O F J Y G P H K P R J K H R X N P Q O I Q K R G P H O Q N E i F Q L J K E L Q G H F c b D j k l F c Q Y G J I Q L Q O J Q L F c K R O G J K R F G H O R J W F c J I I M Y R F M N N O H F Z F J d H Q ] H Y G F Q Y W I R Y R K L R Y Q L Q Y G J ^ R W J H F ` m Case report k Y n Q O K P o p p q c r s Z E H Q O Z R L W N Q G J H Y G \ Q F Q W I J G G H W G R G P H l H N Q O G I H Y G R X O P H M I Q G R L R ] E ^ H K Q M F H R X N R R O ] H Y H O Q L K R Y W J G J R Y c \ H Q [ Y H F F Q Y W N Q J Y J Y G P H f R J Y G F Q Y W I M F K L H F ` t H O I H W J K Q L P J F G R O E F P R \ H W G P Q G F P H P Q W ^ H H Y G O H Q G H W M Y W H O Q W J Q ] Y R F J F R X F H O R Y H ] Q G J d H O P H M I Q G R J W Q O G P O J G J F F J Y K H j M ] M F G o p p u Q Y W G P H G O H Q G I H Y G J Y d R L d H W L R \ Z W R F H K R O G J K R F G H O R J W F Q Y W P E W O R _ E K P L R O R v M J Y H ` w P H N Q G J H Y G W J W Y R G K P H K [ J Y X R O O H ] M L Q O K R Y G O R L F X R O Q L R Y ] H O N H O J R W R X G J I H ` w P H R ^ f H K G J d H x Y W J Y ] F F P R \ H W N Q L H F [ J Y Q Y W d J F J ^ L H I M K R M F I H I ^ O Q Y H F c \ J G P ^ M G G H O y E O Q F P R Y G P H X Q K H c N J G Z G J Y ] H W H I Q R X G P H L R \ H O L H ] Q Y W X R R G W R O F M I c Q F \ H L L Q F F E Y R d J G J F J Y G Q L R K O M O Q L f R J Y G F ` T Q ^ R O Q G R O E x Y W J Y ] F F P R \ H W F H d H O H Q Y H I J Q \ J G P G P H d Q L M H F R X H O E G P O R K E G H F p ` z { _ { p { o h L Q Y W P H I R ] L R ^ J Y z ` s ] h W L c J Y K O H Q F H W L H d H L F R X N O R G H J Y J Y G P H M O J Y H z ` s ] h o z P c W H K O H Q F H W K O H Q G J Y J Y H K L H Q O Q Y K H R X z q I L h I J Y c M O J Y Q O E N O R G H J Y N R F J G J d H S | | | V c O H W M K H W d Q L M H R X K R I N L H I H Y G K R I N R Y H Y G F c Q N R F J G J d H j b j G H F G c Q N R F J G J d H Q Y G J Z W F l b j } o p p k ~ h I L c Q Y G J Z F F l b j N R F J Z G J d H } o p p k ~ h I L ` l M O J Y ] P R F N J G Q L J  Q G J R Y c G P H N Q G J H Y G \ Q F G O H Q G H W \ J G P I H G P E L N O H W Y J F R L R Y H J Y Q W R F H R X { I ] h [ ] h W Q E c Q Y G J ^ J R G J K F Q Y W G O Q Y F X M F J R Y R X N Q K [ H W O H W ^ L R R W K H L L F ` n E K R N P H Y R L Q G H I R X H G J L J Y Q W R F H R X o p p p I ] W Q J L E \ Q F ] J d H Y R Y G P H F H d H Y G P W Q E R X P R F N J G Q L J  Q G J R Y ` l M H G R G P H L R \ d Q L M H R X O H W ^ L R R W K H L L F Q G G P H ^ H ] J Y Y J Y ] R X G O H Q G I H Y G c N M L F H G P H O Q N E \ J G P K E K L R N P R F N P Q I J W H \ Q F Y R G M F H W ` j W Z W J G J R Y Q L \ R O F H Y J Y ] R X G P H W J F H Q F H S L R \ d Q L M H J Y G P H O H W ^ L R R W K H L L F V R K K M O O H W R Y G P H G \ H Y G J H G P W Q E R X G O H Q G I H Y G ` j X G H O H F G Q ^ L J F P H W W H G H O J R O Q G J R Y J Y G P H P H I Q G R N R J H G J K F E F Z G H I c \ H W H K J W H W G R Q W I J Y J F G H O I H G P E L N O H W Y J F R L R Y H N M L F H G P H O Q N E X R O G P O H H W Q E F c Q G Q W Q J L E W R F H R X { p p p I ] N Q O H Y Z G H O Q L ` j X G H O G P H Q ^ R d H I H Y G J R Y H W c F G Q ^ J L J G E J Y O H W ^ L R R W Z L J Y H \ Q F Q K K R I N L J F P H W ` j X G H O G P H P R F N J G Q L G O H Q G I H Y G c P J ] P N O R G H J Y F d Q L M H F J Y M O J Y H r ` z ] h o z P Q Y W O H W M K H W K O H Z Q G J Y J Y H K L H Q O Q Y K H r { I L h I J Y O H I Q J Y H W ` w P H N Q G J H Y G \ Q F W J F K P Q O ] H W \ J G P O H K R I I H Y W Q G J R Y F Q ^ R M G G P H O Q N E \ J G P K R O G J K R F G H O R J W F c I E K R N P H Y R L Q G H I R X H G J L c P E W O R _ E K P L R O R Z v M J Y H c R F G H R N R O R G J K N O R G H K G J R Y Q Y W Q Y G J N L Q G H L H G G P H O Q N E ` w P H N Q G J H Y G P Q W K R I H X R O O H ] M L Q O K P H K [ M N F Q Y W Q G G P H L Q F G K R Y G O R L c J Y D H N G H I ^ H O o p { € c G P H d Q L M H R X N O R G H J Y J Y M O J Y H Q Y W K O H Q G J Y J Y H K L H Q O Q Y K H c Q F \ H L L Q F R G P H O L Q ^ R O Q G R O E N Q Z O Q I H G H O F \ H O H \ J G P J Y Y R O I Q L d Q L M H F ` Discussion w P H K Q F H R X N O H F H Y G H W N Q G J H Y G J F W J F K M F F H W J Y G H O I F R X W J Q ] Y R F J F F E F G H I J K L M N M F H O E G P H I Q G R F M F J Y Q K K R O W Q Y K H \ J G P G P H K O J G H O J Q X R O G P H W J Q ] Y R F J F Q Y W H _ G O H I H L E X Q d R O Q Z ^ L H O H F N R Y F H Q X G H O I H G P E L N O H W Y J F R L R Y H N M L F H G P H O Q N E Q Y W K R Y G J Y M R M F G P H O Q N E \ J G P I E K R N P H Y R L Q G H I R X H G J L ` D E I N Z G R I F Q Y W F J ] Y F J Y R M O K Q F H Q O H I H H G J Y ] G P H K O J G H O J Q X R O W J Q ] Y R F J F ` w P H O H Q O H  R X G P H H L H d H Y K O J G H O J Q X R O G P H K L Q F Z F J x K Q G J R Y R X F E F G H I J K L M N M F H O E G P H I Q G R F M F J Y G P H N Q G J H Y G i I Q L Q O O Q F P c Q O G P O J G J F c [ J W Y H E W J F R O W H O F c P H I Q G R L R ] J K Q L W J F R O W H O F c N R F J G J d H Q Y G J Y M K L H Q O Q Y G J ^ R W E Q Y W Q N R F J G J d H Q Y G J Z W F l b j Q Y W Q Y G J Z F F l b j Q Y G J ^ R W E ` ‚ w P H K Q F H O H N R O G J F F P R \ Y W M H G R G P H J I N R O G Q Y K H R X H Q O L E W J Q ] Y R F J F R X F E F Z G H I J K L M N M F H O E G P H I Q G R F M F c Q Y W H Q O L E Q ] ] O H F F J d H G O H Q G Z I H Y G ` Conclusion l M H G R J Y Q ^ J L J G E G R N H O X R O I [ J W Y H E ^ J R N F E c K L J Y J K Q L Z L Q ^ R Z O Q G R O E Q F F H F F I H Y G J F d H O E J I N R O G Q Y G J Y J Y W J d J W M Q L G P H O Z Q N H M G J K Q N N O R Q K P G R G P H F H N Q G J H Y G F J Y R O W H O G R Q K P J H d H L R Y ] Z G H O I O H I J F F J R Y R X G P H W J F H Q F H ` w P J F K Q F H O H N R O G N O H F H Y G H W G P H N Q G J H Y G \ P R \ Q F G O H Q G H W N O R I N G L E \ J G P Q ] Z ] O H F F J d H G P H O Q N E N M L F H W R F H F R X I H G P E L N O H W Y J F R L R Y H Q Y W P J ] P W R F H F R X I E K R N P H Y R L Q G H I R X H G J L Q Y W \ P R Q K P J H d H W K R I N L H G H L Q ^ R O Q G R O E Q Y W K L J Y J K Q L O H I J F F J R Y R X G P H W J F H Q F H ` Reference { ` t Q O J F F R Y R d Q Y Q H L Q J Y G H O Y H I H W J K J Y H ` { € ` k  W Q Y f H ` U M ] H Y H ƒ O Q Q M Y d Q L W S H G Q L V Z ƒ H R ] O Q W i ƒ Q O W „ x Y … ƒ Q Y Z f Q T M [ Q i † R I Q Y R d o p p z ‡ Y f J ] Q o ` r { { i { q o o o ` D K P M O ˆ t ` ‰ \ H O d J H d R X K L J Y J K Q L I Q Y J X H F G Q G J R Y F R X G P H F E F G H I J K L M N M F H O J G H I Q G R W M F J Y Q W M L G F ` l R F G M N Y R Y Q \ \ \ ` M N G R W Q G H ` K R I ` r ` j M F G J Y t j c ƒ Q L R \ Š U i b Q G M O Q L P J F G R O E Q Y W G O H Q G Z I H Y G R X L M N M F Y H N P O J G J F ` D H I J Y b H N P O R L { q i o c { q q q ` ˆ n J W i q q € o o u  z ` U ] Y H O ‹ ` w P H M F H L Q ^ R O Q G R O E G H F G H F J Y G P H W J Q ] Y R F J F R X D U T ` Š Œ L J Y ˆ Q G P R L o p p p … € r i z o z Z r o `  Ž Ž  + 2 2 (  . ( ) * . ) 5 ‘ 2 , . , , ’ 7 2 “ ”  . 0 ’ . 7 . 8 = 8 • – * ( + , — , , 1 — — • – > * ( + • – > , 1 ’ , = ’ Odgovor na terapiju mikofenolat mofetilom kod pacijentice sa teškim oblikom sistemskog eritemskog lupusa SAŽETAK Sistemski eritemski lupus (SEL) je bolest nepoznate etiologije u kojoj su tkiva i ćelije oštećeni patogenim autoantitijelima i imunskim kompleksima. 90% oboljelih su žene, a starosna dob u kojoj najčešće oboljevaju je između 20. i 40. godine života. Bolest može zahvatiti samo jedan organski sistem, a može biti i višesistemska i zahvatiti kožu, zglobove, bubrege, pluća, nervni sistem i serozne membrane. U radu je prikazan slučaj 38-ogodišnje pacijentice sa teškim oblikom sistemskog eritemskog lupusa, koji je adekvatno odreagovao na terapiju mikofenolat mofetilom. Ključne riječi: Sistemski eritemski lupus, efekat terapije, mikofenolat mofetil 75 LJ. BOŽIĆ-MAJSTOROVIĆ, B. GAŠIĆ, D. JOVIĆ, M. VUKČEVIĆ, J. AĆIMOVIĆ